BioMarin Pharmaceutical (BMRN) Price Target Raised to $145 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study
June 17, 2015 4:01 PM EDT- 50% Increase in mean annualized growth velocity in 15 µg/kg/daily dose group
- BMN 111 was well tolerated across all three dose cohorts
- Phase 2 findings support program advancement of 15µg/kg/daily dose into pivotal registration discussions with health authorities
- Investor conference call to be held today, June 17, 2015 at 1:30pm PT/(4:30pm ET)
SAN RAFAEL, Calif., June 17, 2015 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced positive results of a Phase 2 proof-of-concept and dose finding study of BMN 111... More
